Literature DB >> 191541

Specific impairment of cell-mediated immunity in mothers of infants with congenital infection due to cytomegalovirus.

M Rola-Pleszczynski, L D Frenkel, D A Fuccillo, S A Hensen, M M Vincent, D W Reynolds, S Stagno, J A Bellanti.   

Abstract

Specific lymphocyte-mediated cytotoxicity to cytomegalovirus (CMV) in eight infants (six to 27 months old) with congenital CMV infection and in the mothers of six of these infants was evaluated with use of a 51chromium (51Cr)-release microassay. The control population consisted of 25 normal newborns, children, and adults. The titers of indirect hemagglutinating (IHA) antibody to CMV in the infected infants ranged from 1:16 to 1:1,024. All of these infants had detectable specific immune release of 51Cr that ranged from 3.3% to 48.9% (mean +/-SE, 21.0%+/-5.6%). The mothers of these infants demonstrated significantly elevated titers of IHA antibody to CMV (geometric mean titer, 1:410) as compared with a mean titer of 1:22 in controls (t = 5.71; P less than 0.001) but showed significantly depressed specific immune release (9.2% +/- 3.2%) compared with that of normal seropositive controls (24.8% +/- 2.8%; t = 3.31; P less than 0.001). In addition, two adult nulliparous women with persistent CMV viruria were also found to have depressed specific immune release to CMV (10.8% and 16.2%). These data suggest that a specific impairment in cell-mediated immunity to CMV occurs in mothers of infants with congenital CMV infection and in some persons who persistently excrete CMV.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 191541     DOI: 10.1093/infdis/135.3.386

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

2.  Susceptibility of lymphoblastoid cells to infection with human cytomegalovirus.

Authors:  M J Tocci; S C St Jeor
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

3.  Cellular immune response to cytomegalovirus infection after renal transplantation.

Authors:  C C Linnemann; C A Kauffman; M R First; G M Schiff; J P Phair
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

4.  Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy.

Authors:  K Schopfer; E Lauber; U Krech
Journal:  Arch Dis Child       Date:  1978-07       Impact factor: 3.791

5.  Immunoglobulin G to virus-specific early antigens in congenital, primary, and reactivated human cytomegalovirus infections.

Authors:  G Gerna; P M Cereda; E Cattaneo; G Achilli; M G Revello
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

6.  Cytomegalovirus-specific cytotoxicity mediated by non-T lymphocytes from peripheral blood of normal volunteers.

Authors:  N Kirmani; R K Ginn; K K Mittal; J F Manischewitz; G V Quinnan
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

7.  Cytomegalovirus-specific cell-mediated immunity in lower-socioeconomic-class adolescent women with local cytomegalovirus infections.

Authors:  R G Faix; S E Zweig; J F Kummer; D Moore; D J Lang
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

8.  Longitudinal studies of cytomegalovirus-specific cell-mediated immunity in congenitally infected infants.

Authors:  M Okabe; S Chiba; T Tamura; Y Chiba; T Nakao
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

9.  Delayed hypersensitivity to murine cytomegalovirus and its depression during pregnancy.

Authors:  K T Chong; C A Mims
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

10.  Cytomegalovirus infection in infancy: virological and immunological studies.

Authors:  R C Gehrz; K M Linner; W R Christianson; A E Ohm; H H Balfour
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.